Home＞ACADEMIA
DPP-4 Inhibitor Prevents Deterioration in Cardiac Diastolic Function in Diabetes Patients: Research Sub-Analysis(May.26.2017)
The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin significantly inhibited deterioration in cardiac diastolic function in diabetes patients, according to results of a clinical research sub-analysis announced by Saga University on May 24 ...
(LOG IN FOR FULL STORY)
-
- Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors Jul.11
-
Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
Jul.05
- Anti-TNF-α Antibody Treatment for Crohn’s Disease Costs 1.95 Million Yen per Patient Annually: Study Jun.27
- Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment Jun.26
-
Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
Jun.21
- Lilly Japan Marks Opening of New Kobe Headquarters(Jul.17)
- Boehringer’s DPP-4/SGLT2 Combo Up for MHLW Panel Review on July 27(Jul.17)
- Taiho Exercises Option to Gain Asian Rights to Arcus’ I/O Candidate(Jul.17)
- Takeda Jettisons Japan Rights to Obesity Drug OBLEAN after Long Listing Limbo(Jul.17)
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices(Jul.17)
